Acadian Asset Management
ARDS

Acadian Asset Management’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Acadian Asset Management’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,533
Closed -$8K – 1920
2023
Q2 		$8K Hold
36,533
– – ﹤0.01% 1682
2023
Q1 		$11K Buy
+36,533
New +$26.5K ﹤0.01% 1686

Other funds holding ARDS

WA
Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Acadian Asset Management's ARDS Position: Q3 2023 in Review

Acadian Asset Management sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 36,533 shares — an estimated $8K sold.

Acadian Asset Management first reported a position in ARDS in Q1 2023 and held it in 2 quarters. The position peaked at $11K in Q1 2023. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

  • Acadian Asset Management reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Acadian Asset Management sold 36,533 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $8K.
  • Acadian Asset Management first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Acadian Asset Management's Aridis Pharmaceuticals Inc. Common Stock position peaked at $11K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.